Cost of Achieving HbA1c Treatment Targets and Weight Loss Responses with Once-Weekly Semaglutide Versus Dulaglutide in the United States

ConclusionsThe cost of bringing one patient to the triple composite endpoint of an HbA1c  <  7% without hypoglycemia and no weight gain would be 28% and 68% higher with dulaglutide 1.5 mg relative to once-weekly semaglutide 1.0 mg and dulaglutide 0.75 mg relative to once-weekly semaglutide 0.5 mg, respectively. Once-weekly semaglutide therefore provides better value for money than du laglutide for the treatment of people with T2D in the USA.FundingNovo Nordisk A/S.
Source: Diabetes Therapy - Category: Endocrinology Source Type: research